Koers Ligand Pharmaceuticals Inc. OTC Bulletin Board
Aandelen
US53220K1815
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
|
Omzet 2024 * | 138 mln. 129 mln. | Omzet 2025 * | 157 mln. 147 mln. | Marktkapitalisatie | 1,51 mld. 1,41 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 92 mln. 85,89 mln. | Nettowinst (verlies) 2025 * | 50 mln. 46,68 mln. | EV/omzet 2024 * | 11 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 9,61 x |
K/w-verhouding 2024 * |
16,8
x | K/w-verhouding 2025 * |
26,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,65% |
Recentste transcriptie over Ligand Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 01-03-07 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 01-11-22 |
President | 49 | 06-08-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 01-03-03 |
John LaMattina
BRD | Director/Board Member | 74 | 01-02-11 |
Stephen Sabba
BRD | Director/Board Member | 64 | 04-08-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,32% | 815 mld. | |
+44,05% | 641 mld. | |
-6,75% | 352 mld. | |
+13,56% | 314 mld. | |
+10,68% | 303 mld. | |
+16,57% | 242 mld. | |
+13,31% | 218 mld. | |
+8,48% | 168 mld. | |
-2,81% | 159 mld. |
- Beurs
- Aandelen
- Koers LGND
- Koers